Bolt Biotherapeutics (NASDAQ:BOLT) Posts Quarterly Earnings Results, Misses Estimates By $1.18 EPS

Bolt Biotherapeutics (NASDAQ:BOLT) released its quarterly earnings results on Tuesday. The company reported ($4.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18), FiscalAI reports. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.50 million.

Bolt Biotherapeutics Trading Down 0.3%

NASDAQ BOLT traded down $0.01 during trading hours on Tuesday, reaching $3.98. The company’s stock had a trading volume of 10,182 shares, compared to its average volume of 24,902. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.51 and a quick ratio of 3.51. Bolt Biotherapeutics has a 52 week low of $3.75 and a 52 week high of $7.20. The stock has a market cap of $7.65 million, a P/E ratio of -0.24 and a beta of 1.18. The firm has a fifty day simple moving average of $4.17 and a 200-day simple moving average of $4.65.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC raised its position in shares of Bolt Biotherapeutics by 92.2% during the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after acquiring an additional 26,400 shares during the last quarter. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics in the third quarter valued at approximately $89,000. Shay Capital LLC acquired a new stake in Bolt Biotherapeutics during the 3rd quarter valued at approximately $85,000. Finally, Squarepoint Ops LLC increased its position in Bolt Biotherapeutics by 19.8% during the 3rd quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the period. Institutional investors own 86.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on BOLT. Rodman & Renshaw initiated coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $22.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $34.67.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.